Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger,
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …

The superfamily of cyclic nucleotide (cN) phosphodiesterases (PDEs) is comprised of 11
families of enzymes. PDEs break down cAMP and/or cGMP and are major determinants of …

Prostate cancer (PC) is a slowly progressing malignancy that often responds to androgen
ablation or chemotherapy by becoming more aggressive, acquiring a neuroendocrine …

Cholesterol provided by low-or high-density lipoprotein is the precursor for biosynthesis of
progesterone. Once inside the cell, cholesterol can be used for steroidogenesis or esterified …

It is now well established that the NO-sGC-cGMP signal transduction system mediates many
different physiological functions in almost every conceivable organ system; this has been …

Context Several preclinical reports, randomized controlled trials, systematic reviews, and
posthoc analyses corroborate the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in …

Objectives We have previously described the antifibrotic role of the soluble guanylate
cyclase (sGC). The mode of action, however, remained elusive. In the present study, we …

Benign prostatic hyperplasia (BPH) is the major cause of lower urinary tract symptoms in
men aged 50 or older. Symptoms are not normally life threatening, but often drastically affect …

Introduction: In men, lower urinary tract symptoms (LUTS) are primarily attributed to benign
prostatic hyperplasia (BPH). Therapeutic options are targeted to relax prostate smooth …

Abstract BACKGROUND Phosphodiesterase type 5 (PDE5) inhibitors improve benign
prostatic hyperplasia (BPH)‐related lower urinary tract symptoms (LUTS), often associated …